Perspectiva general
Join Us for the Ten Year Special Planning Anniversary at DIA China 10th Annual Meeting
Every year at May, the DIA China Annual Meeting, which includes the whole chain of drug R&D and focuses on clinical and regulatory science, has become the most important opportunities to exchange ideas and practices, expand network and display products & services in China healthcare community.
The 10th DIA China Annual Meeting from May 22-25, 2018 will bring together more than 2000 pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments.
Special DIAmond Sessions will introduce global views into our perspective of the Chinese pharmaceutical ecosystem. Sessions will model the experience from the global DIA 2017 Annual Meeting in the US. As the largest multidisciplinary event in DIA Asia, other highlights will include 100+ exhibit booths and a new, unique hub for R&D and emerging companies to showcase themselves in “Innovation Hub.”
Professionals involved at all levels in the regulation, discovery, development, and life cycle management of health care products, will travel from China and around the world to witness transformational changes for China’s innovation and regulatory environment, to share the view points, knowledge, new technologic progress, and cross-cutting collaboration towards patient centric biopharma innovation in China.
Comité del programa
-
Pei HU Director, Phase I Unit, Clinical Pharmacological Research Center
Peking Union Medical College, China -
Bin Xue Director-General
China Center for Food and Drug International Exchange, NMPA, China -
Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Senior Advisor
BeiGene (Beijing) Co., Ltd., China -
Irene Deng Head of Regulatory Affairs, China
Sanofi, China -
Jin Cui Program Officer
China Center for Food and Drug International Exchange , China -
George LIU Head of Early Development and Scientific Operation
Harbour Biomed, China -
Zhiqiang Ning Vice President, Research & Clinical Development
Shenzhen Chipscreen Biosciences, Ltd., China -
Jessica Liu, MD VP, Head of Merges and Acquisition Management Department
Tigermed Consulting Co., Ltd, China -
Sunny Zhu Chief Medical Officer, Infectious Diseases
Everest Medicines, China -
Hannah Chen, MD Consultant
Beijing XiaoTongMingDa Technology Ltd., China -
Paul Dai, MD Head of Clinical Operations
TDC, Asia, Takeda, China -
Reako Ren Head of SMO Services
WuXi AppTec, China -
Connie Dai
Graceful Plume, China -
Hualong Sun General manager
Meta Clinical Technical Co. Ltd, China -
Charles Yan Vice President, Head of Clinical Data Science Center
Jiangsu Hengrui, China -
Melly Lin, MS CMC Regulatory Policy Lead, Pharma Technical Regulatory
F. Hoffmann-La Roche Ltd, Switzerland -
Joe Zhang Co-founder and CEO
BJ Bioscience Inc., China -
Xiangyang Zhu CEO
Shanghai Huaota Biopharma Co., Ltd, China -
Li L Wang Global Senior Vice President & Head, Lilly China Drug Development & Medical Affa
Eli Lily & Company, China -
Xiaoling Wang Clinical Documentation
Clinical Science Operation, Sanofi R&D China, China -
Xue TANG Drug Safety Unit Regional Head (DRH),
APAC Pfizer, China -
Dayao ZHAO, MD, PhD Former Vice President and Lead, China Drug Development
Pfizer, China -
Jane Y. Cai, PhD Former Managing Director
DIA China, China -
Tony Guo Executive Director, Head of Biometrics China
BeiGene, China -
Tong Guo CEO
GEM Flower Pharma Tech, China -
Amber Wang Vice President, Regulatory Affairs & QA
SmithNephew, China -
Ruyi He, MD Chief Scientist
Center for Drug Evaluation, CFDA, United States -
Jingsong Wang, MD Founder, Chairman, and Chief Executive Officer
Harbour BioMed, China -
Shun Lu Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital,
Shanghai Jiaotong University, China -
Xianglin Zhang President
Shenyang Pharmaceutical University, China -
Carol Zhu, MBA Vice President, Portfolio and Project Management
JW Therapeutics, China -
Ron Fitzmartin, PhD, MBA Senior Advisor, Office of Regulatory Operations, CBER
FDA, United States -
Murray M. Lumpkin, DrMed, MD, MSc Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative
Bill and Melinda Gates Foundation, United States -
Kenneth Getz, MBA Tufts Center for the Study of Drug Development
Tufts University School of Medicine, United States -
Sandy Milligan, JD, MD Board of Director Member, Gossamer Bio; Principal
Innovex Strategies, United States -
Ling Su, PhD Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China
¿Tiene una cuenta?